• Participants must have a documented diagnosis of MM.

• Participants with measurable disease defined as at least one of the following:

‣ Serum M-protein ≥0.5 g/dL measured using serum protein immunoelectrophoresis and/or

⁃ Urine M-protein ≥200 mg/24 hours measured using urine protein immunoelectrophoresis and/or

⁃ Serum free light chain (FLC) assay: Involved FLC assay ≥10 mg/dL (≥100 mg/L) and an abnormal serum FLC ratio (\<0.26 or \>1.65).

• Participants with relapsed and/or refractory MM with at least 1 prior line of therapy and no more than 3 prior lines of therapy.

• Contraceptive use by \[men and women\] should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

‣ Male participants agree to practice true abstinence or agree to use contraception while receiving study treatment, during dose interruptions and at least 5 months following study treatment discontinuation, even if has undergone a successful vasectomy.

⁃ A female participant is eligible to participate if she is not pregnant, not breastfeeding, and either is not a female of childbearing potential (FCBP XE FCBP \f Abbreviation \t female of childbearing potential ) or agrees to practice complete abstinence or use contraception.

• Capable of giving signed informed consent.